RxDoctor Payments Data

Vedvati Patel, MD

Nephrology · Chicago, ILNPI 1326247966

Payments from drug & device makers

$4,004in general payments, 2019–2025

Across 55 payments — averaging $72.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Travere Therapeutics, Inc.$634
  • Boehringer Ingelheim$288
  • Lilly USA, LLC$227
  • Bayer$213
  • Mallinckrodt Hospital Products Inc.$177
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,004 in reported general payments places this provider in the 75th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$124,168
Medicare patients
154
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide15$22,308
Sevelamer Carbonate74$10,523
Nifedipine ErNifedipine42$568
Hydralazine Hcl18$391
Metolazone14$360
Carvedilol12$226
Amlodipine Besylate16$206
Atorvastatin Calcium15$199
Furosemide19$114
Losartan Potassium14$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$50$22,30815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 524 nephrology providers in Illinois.

Other nephrology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →